Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13457441 | 0.92 | LMNA (0.66) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL12562095 | 0.86 | TP53 (0.77) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL13457193 | 0.84 | TP53 (0.58) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL1987445 | 0.84 | LMNA (0.57) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL1991091 | 0.82 | ROCK2 (1.00) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL12756749 | 0.79 | TP53 (0.56) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL1987269 | 0.78 | ROCK2 (0.69) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL13798682 | 0.78 | ROCK2 (0.68) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL12602331 | 0.78 | TP53 (0.71) | ROCK2LMNATP53POLBMAPT | |
| SCHEMBL7959431 | 0.77 | TP53 (0.54) | ROCK2LMNATP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, RHOT2 | ROCK2 4/4885LMNA 2482/4885TP53 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.